I'm calling meeting number 24 to order.
Today's meeting of the House of Commons Standing Committee on International Trade is webcast and is taking place in the hybrid format, pursuant to the House order of January 25, 2021.
I welcome all my colleagues back today on a beautiful Monday morning, and the start of, hopefully, a very successful week.
Pursuant to Standing Order 108 and the motion adopted by the committee on March 12, 2021, the committee will proceed with its study of Canada's international trade and investment policy with regard to selected considerations concerning the COVID-19 vaccines.
I'd like to welcome our witnesses this morning.
We have, as an individual, Brian Daley, lawyer and partner, Norton Rose Fulbright Canada. Hopefully, he's going to get hooked up to join the committee proceedings.
We have Marc-André Gagnon, associate professor, School of Public Policy and Administration, Carleton University.
From the Canadian Chamber of Commerce, we have Mark Agnew, vice-president, policy and international, and from Providence Therapeutics, we have Brad Sorenson, chief executive officer.
Professor Gagnon, you have the floor.